Bluebird Bio is a biotechnology company focused on developing gene therapies for severe genetic diseases and cancer. The company uses gene editing and gene therapy technologies to treat conditions like sickle cell disease, beta-thalassemia, and various cancers. Bluebird Bio has achieved regulatory approvals for several gene therapies in Europe and continues to advance multiple programs through clinical trials. The company represents the cutting edge of gene therapy development and personalized medicine.
Bluebird Bio has received investment from 1 venture capital firm.
Biotechnology company developing gene therapies for severe genetic diseases and cancer using advanced gene editing technologies.
Bluebird Bio has received investment from Third Rock Ventures. These venture capital firms and investors provide both capital and strategic support.
Bluebird Bio has raised $1.2B in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Bluebird Bio was founded in 2010 and is headquartered in Somerville, MA.
Bluebird Bio operates in the Biotech sector. Biotechnology company developing gene therapies for severe genetic diseases and cancer using advanced gene editing technologies.
